The Efficacy and Safety of Homoharringtonine Added to Venetoclax and Azacitidine in the Frontline Treatment of Newly Diagnosed Acute Myeloid Leukemia, a Multi-Center Exploratory Cohort Study

被引：0
|
作者：
Yu, Guopan [1 ]
Yao, Zurong [1 ]
Yin, Zhao [1 ]
Zhang, Yu [1 ]
Zhao, Weihua [2 ]
Weng, Guangyang [3 ]
Guo, Ziwen [4 ]
Sun, Zhiqiang [5 ]
Shi, Pengcheng [1 ]
Jiang, Xuejie [6 ]
Xu, Dan [1 ]
Xuan, Li [1 ]
Liu, Qifa [1 ]
机构：
[1] Southern Med Univ, Nanfang Hosp, Dept Hematol, Guangzhou, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Dept Hematol, Nanning, Peoples R China
[3] Shenzhen Second Peoples Hosp, Dept Hematol, Shenzhen, Peoples R China
[4] Zhongshan City Peoples Hosp, Dept Hematol, Zhongshan, Peoples R China
[5] Southern Med Univ, Shenzhen Hosp, Dept Hematol, Shenzhen, Peoples R China
[6] Guangzhou Med Univ, Affiliated Hosp 2, Dept Hematol, Guangzhou, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
homoharringtonine; venetoclax/azacitidine; acute myeloid leukemia; efficacy; safety;
D O I：
10.1182/blood-2024-206872
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：4283 / 4283
页数：1
相关论文
共 50 条
  • [21] Homoharringtonine as a backbone drug for the treatment of newly diagnosed pediatric acute myeloid leukemia: a report from a single institution in China
    JingYan Tang
    Yin Liu
    Jing Chen
    Huiliang Xue
    Ci Pan
    LongJun Gu
    International Journal of Hematology, 2011, 93 : 610 - 617
  • [22] The efficacy and safety of a homoharringtonine-based protocol for children with acute myeloid leukemia: A retrospective study in China
    Tang, Yanjing
    Luo, Chengjuan
    Shen, Shuhong
    Xue, Huiliang
    Pan, Ci
    Hu, Wenting
    Chen, Xiaoxiao
    Cai, Jiaoyang
    Chen, Jing
    Tang, Jingyan
    PEDIATRIC HEMATOLOGY AND ONCOLOGY, 2021, 38 (02) : 97 - 107
  • [23] Cusatuzumab plus azacitidine in Japanese patients with newly diagnosed acute myeloid leukemia ineligible for intensive treatment
    Ikezoe, Takayuki
    Usuki, Kensuke
    Aida, Kensuke
    Hatayama, Tomoyoshi
    Shirahase, Toru
    Yamauchi, Takahiro
    CANCER SCIENCE, 2023, 114 (03) : 1037 - 1044
  • [24] How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia
    Jonas, Brian A.
    Pollyea, Daniel A.
    LEUKEMIA, 2019, 33 (12) : 2795 - 2804
  • [25] A phase 2 study of chidamide in combination with CAG and venetoclax-azacitidine in acute myeloid leukemia: Clinical safety, efficacy, and correlative analysis
    Yang, Jingjing
    Liu, Qingyang
    Zhang, Xiawei
    Jing, Yu
    Le, Ning
    Li, Meng
    Xu, Lingmin
    Zhao, Weijia
    Huang, Sai
    Liu, Daihong
    Dou, Liping
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2025, 151
  • [26] Efficacy and safety of decitabine combined with HAAG (homoharringtonine, aclarubicin, low-dose cytarabine and G-CSF) for newly diagnosed acute myeloid leukemia
    Zhu, Jun-Feng
    Dai, Hai-Ping
    Zhang, Qian-Qian
    Yin, Jia
    Li, Zheng
    Cui, Qin-Ya
    Tian, Xiao-Peng
    Liu, Si-Ning
    Jin, Zheng-Ming
    Zhu, Xia-Ming
    Wu, De-Pei
    Tang, Xiao-Wen
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [27] AVALON: The Italian cohort study on real-life efficacy of hypomethylating agents plus venetoclax in newly diagnosed or relapsed/refractory patients with acute myeloid leukemia
    Todisco, Elisabetta
    Papayannidis, Cristina
    Fracchiolla, Nicola
    Petracci, Elisabetta
    Zingaretti, Chiara
    Vetro, Calogero
    Martelli, Maria Paola
    Zappasodi, Patrizia
    Di Renzo, Nicola
    Gallo, Susanna
    Audisio, Ernesta
    Griguolo, Davide
    Cerchione, Claudio
    Selleri, Carmine
    Mattei, Daniele
    Bernardi, Massimo
    Fumagalli, Monica
    Rizzuto, Giuliana
    Facchini, Luca
    Basilico, Claudia Maria
    Manfra, Ilenia
    Borlenghi, Erika
    Cairoli, Roberto
    Salutari, Prassede
    Gottardi, Michele
    Molteni, Alfredo
    Martini, Vincenza
    Lunghi, Monia
    Fianchi, Luana
    Cilloni, Daniela
    Lanza, Francesco
    Abruzzese, Elisabetta
    Cascavilla, Nicola
    Rivellini, Flavia
    Ferrara, Felicetto
    Maurillo, Luca
    Nanni, Jacopo
    Romano, Alessandra
    Cardinali, Valeria
    Gigli, Federica
    Roncoroni, Elisa
    Federico, Vincenzo
    Marconi, Giovanni
    Volpi, Roberta
    Sciume, Mariarita
    Tarella, Corrado
    Rossi, Giuseppe
    Martinelli, Giovanni
    CANCER, 2023, 129 (07) : 992 - 1004
  • [28] High efficacy of Azacitidine plus HAG in acute myeloid leukemia: an open-label, single-arm, multi-center, phase 2 study
    Li, Jun
    Han, Qi
    Huang, Yanqing
    Wei, Yanhui
    Zi, Jie
    Zhao, Lidong
    Cai, Zhimei
    Lu, Xuzhang
    Xiao, Rong
    Zhang, Yanming
    Yang, Xiaotian
    Xu, Hao
    Sun, Naitong
    Zhuang, Wanchuan
    Wu, Zhengdong
    Xia, Yuan
    Xu, Yanli
    He, Bin
    Zhu, Wei
    Min, Fengling
    Chen, Yongchun
    Ding, Banghe
    Shi, Peimin
    Xie, Jing
    Tang, Hua
    Liu, Zefa
    Li, Bingzong
    Sun, Yu
    Qiu, Hongxia
    Duan, Limin
    Dovat, Elanora
    Song, Chunhua
    SzeKely, Laszlo
    Dovat, Sinisa
    Ge, Zheng
    BLOOD CANCER JOURNAL, 2022, 12 (10)
  • [29] Ivosidenib plus Azacitidine vs Placebo plus Azacitidine in Patients With Newly-Diagnosed Acute Myeloid Leukemia: Updated Long-term Efficacy and Safety Results From the AGILE Study
    de Botton, Stephane
    Montesinos, Pau
    Polo, Susana Vives
    Zarzycka, Ewa
    Wang, Jianxiang
    Riva, Marta
    Heuser, Michael
    Calado, Rodrigo T.
    Schuh, Andre C.
    Yeh, Su-Peng
    Hui, Jianan
    Gianolio, Diego A.
    Patel, Prapti
    Recher, Christian
    Doehner, Hartmut
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S304 - S304
  • [30] Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
    Mustafa Ali, Moaath K.
    Corley, Elizabeth M.
    Alharthy, Hanan
    Kline, Kathryn A. F.
    Law, Jennie Y.
    Lee, Seung Tae
    Niyongere, Sandrine
    Duong, Vu H.
    Emadi, Ashkan
    Baer, Maria R.
    FRONTIERS IN ONCOLOGY, 2022, 12
12345